Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (8938)	9/23/2001 12:06:59 PM
From: Biotech Jim	Read Replies (1) \| Respond to of 9719

Not only do they have to run additional trials, but in androgen-dependent prostate disease I suspect they need to show improvement in outcomes measures, and these data will be more costly to generate than were the previous trials. This type of clinical data, in the absence of an established surrogate marker, will be required IMO to get the appropriate labeling to achieve optimal sales. There was also a statement of the loss of efficacy (perhaps either LH or androgen levels) after some time of treatment. I have neither a specific citation or data to such, can anyone help me out here? Jim